Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Journey Medical (DERM) Research & Development (2021 - 2025)

Journey Medical filings provide 5 years of Research & Development readings, the most recent being $154000.0 for Q4 2025.

  • On a quarterly basis, Research & Development fell 29.36% to $154000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $480000.0, a 95.13% decrease, with the full-year FY2025 number at $480000.0, down 95.13% from a year prior.
  • Research & Development hit $154000.0 in Q4 2025 for Journey Medical, down from $287000.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $7.9 million in Q1 2024 to a low of $29000.0 in Q2 2021.
  • Median Research & Development over the past 5 years was $1.4 million (2022), compared with a mean of $1.8 million.
  • Biggest five-year swings in Research & Development: soared 8896.55% in 2022 and later plummeted 99.51% in 2025.
  • Journey Medical's Research & Development stood at $2.0 million in 2021, then soared by 113.65% to $4.3 million in 2022, then crashed by 64.64% to $1.5 million in 2023, then plummeted by 85.51% to $218000.0 in 2024, then fell by 29.36% to $154000.0 in 2025.
  • The last three reported values for Research & Development were $154000.0 (Q4 2025), $287000.0 (Q3 2025), and $39000.0 (Q1 2025) per Business Quant data.